Incyte | INCY - Betriebsergebnis





Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03